Kiniksa Pharmaceuticals International (KNSA) Payables (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Payables for 10 consecutive years, with $12.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 38.5% year-over-year to $12.4 million; the trailing twelve-month figure through Jun 2026 stood at $12.4 million (up 38.5% YoY), and the FY2025 full-year result was $2.0 million, down 0.54% from the prior year.
• Payables fell to $12.4 million in Q2 2026 per KNSA's latest filing, from $24.4 million in the prior quarter.
• Across five years, Payables topped out at $24.4 million in Q1 2026 and bottomed at $648000.0 in Q2 2023.
• Historically, Payables has averaged $5.9 million across 5 years, with a median of $4.5 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Payables tumbled 75.27% in 2024, then soared 1131.18% in 2026.
• Over 5 years, Payables stood at $7.9 million in 2022, then grew by 4.39% to $8.2 million in 2023, then sank by 75.27% to $2.0 million in 2024, then retreated by 0.54% to $2.0 million in 2025, then jumped by 511.64% to $12.4 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $12.4 million, $24.4 million, and $2.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.